View Rule
View EO 12866 Meetings | Printer-Friendly Version Download RIN Data in XML |
TREAS/IRS | RIN: 1545-BM26 | Publication ID: Fall 2016 |
Title: Branded Prescription Drug Fee | |
Abstract:
This proposed regulation modifies the definition or the term "controlled group" in 26 CFR 51.2T. |
|
Agency: Department of the Treasury(TREAS) | Priority: Substantive, Nonsignificant |
RIN Status: Previously published in the Unified Agenda | Agenda Stage of Rulemaking: Final Rule Stage |
Major: No | Unfunded Mandates: No |
CFR Citation: 26 CFR 51 | |
Legal Authority: 26 U.S.C. 7805 26 U.S.C. 9008 Pub. L. 111-347 Affordable Care Act |
Legal Deadline:
None |
||||||||||||
Timetable:
|
Additional Information: REG-123286-14 Drafting attorney: Celia Gabrysh (202) 317-6855 Reviewing attorney: Charles Langley (202) 317-6855 Treasury attorney: CC: PSI | |
Regulatory Flexibility Analysis Required: No | Government Levels Affected: Undetermined |
Small Entities Affected: No | Federalism: No |
Included in the Regulatory Plan: No | |
RIN Data Printed in the FR: No | |
Related RINs: Related to 1545-BM27 | |
Agency Contact: Celia Gabrysh Attorney-Advisor (Tax) Department of the Treasury Internal Revenue Service 1111 Constitution Avenue NW., Room 5309, Washington, DC 20224 Phone:202 317-6855 Fax:202 317-6733 Email: celia.gabrysh@irscounsel.treas.gov |